Saint-Gobain: 73% of the 2012 Dividend Will be Reinvested

Date: 15 July 2013
Source: Saint-Gobain
Saint-Gobain shareholders responded favorably to the dividend reinvestment option, with 72.5% of the total dividend to be paid in stock.

This high reinvestment rate allows Saint-Gobain to strengthen its equity by €474 million.  

A total of nearly 16.9 million new shares will be issued, equivalent to 3.1% of outstanding shares.

The new shares will be issued and delivered on July 5. They will carry rights to the 2013 dividend and will rank pari passu to existing shares from the issue date. The new shares will be listed on NYSE Euronext Paris on July 5.

The share issue will have the effect of increasing Compagnie de Saint-Gobain's share capital as of July 5 to €2,211 million, represented by 552.7 million ordinary shares with a par value of €4 each, all fully paid and all in the same class.

Cash dividends will also be paid on July 5, for a total of €180 million.

During the Annual General Meeting of June 6, Saint-Gobain shareholders approved payment of a 2012 dividend of €1.24 per share and the option to receive the dividend in cash or in Saint-Gobain shares issued at a price of €28.12 per share. Shareholders that chose the stock dividend alternative were required to notify the Company between June 12 and June 26.

600450 Saint-Gobain: 73% of the 2012 Dividend Will be Reinvested

See more news about:

Others also read

A bright future is ahead for glass, thanks to a serious focus on innovation, the environment, and sustainability, the industry’s annual prestige awards ceremony at the Millennium Gallery in Sheffield heard. (Thurs 22 November).
Let’s re-live the event highlights together.
Saint-Gobain has approved the most important operation planned in Europe, which will be carried out over the next two years.
The façade of the RAL building in Bonn unmistakeably showcases the identity of the client and user of the building.
Glassolutions’ Installation business has relaunched as Facades & Glazing Solutions UK Ltd (FGS) following its sale to private investment firm CoBe Capital.
SUPERCONTRYX - a lead glass should be an extremely important element of your medical facility’s X-ray protection strategy as it attenuates the effect of radiations significantly.

Add new comment